“High research costs and falling patient enrolment numbers are factors which have greatly influenced the continued globalization of clinical trials, with many multinational and biotech companies targeting developing and emerging countries for clinical research. One of the most popular LATAM countries for clinical trials at present is Mexico due to its high population, its strategic location near North America and its stable economic and political status since the 1993 NAFTA (North American Free Trade Agreement).
Fisher Clinical Services Mexico was established in 2008. We provide a breadth of services at local level, from importation to secondary packaging, comparator sourcing, labeling, storage and distribution, all the way through to destruction. We invite you to find out more about our facility.”
Nora Hernandez Country Manager, Fisher Clinical Services, Mexico
Fast Facts on Mexico and the Healthcare Industry:
- Mexico is the world’s 9th largest pharmaceutical market
- Mexico has the 2nd largest population in LATAM and Mexico city is the most densely populated city in the world
- Mexico is the 2nd country that conducts the largest number of clinical trials in Latin America. Argentina and Brazil are other popular LATAM countries for clinical trials.
- Mexico has a high percentage of the adult population not previously involved in clinical trials – ideal patient recruits for trials on Alzheimer, Parkinson, osteoporosis, cardiovascular and rheumatoid illnesses
- The regulatory entity in Mexico is COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- Many clinical trial studies are submitted by institutions, such as large hospitals, in representation of pharmaceutical companies and biotechs that do not have a presence in this country